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Introduction: Treatment with a topoisomerase I inhibitor in com-
bination with a platinum results in superior or equal survival com-
pared with etoposide-based treatment in extensive disease small cell
lung cancer (SCLC). Five-day topotecan is inconvenient and there-
fore shorter schedules of topotecan and cisplatin are needed. The
aim of this phase II study was to establish the response rate and
response duration in chemo-naive patients with SCLC receiving a
3-day topotecan and cisplatin schedule.
Methods: Simons optimal two-stage design was used. Patients with
previously untreated extensive disease SCLC, adequate organ func-
tions and performance status less than 3 were eligible. Topotecan
(2.0 mg/m2, intravenously) was administered on days 1 to 3 with
cisplatin (50 mg/m2, intravenously) on day 3 every 3 weeks for a
total of six cycles.
Results: Forty-three patients received 219 cycles of chemotherapy.
Median age was 59 (range 44–74), 79% had performance status 0 or
1. Thirty-one patients completed all six cycles. Grade 3/4 anemia,
neutrocytopenia, and thrombocytopenia were recorded in 9.5%,
66.7%, and 21.4% of patients, respectively. Fourteen percent of
patients experienced neutropenic fever. No episodes of fatal sepsis
occurred. Non-hematologic toxicity was mild and manageable.
Overall and complete response rates were 72.1% and 9.3%, respec-
tively. The median overall survival and response duration were 10.3
months (95% confidence interval: 8.6–12.0) and 7.0 months (95%
confidence interval: 6.3–7.7), respectively.
Conclusion: Three-day topotecan with cisplatin on day 3 is active
and safe in extensive disease SCLC. An ongoing phase III random-
ized trial compares this combination to standard treatment.
Key Words: Small cell lung cancer, Extensive disease, Topotecan,
Cisplatin, Phase II.
(J Thorac Oncol. 2008;3: 902–906)
The progress in the treatment of extensive disease smallcell lung cancer (SCLC) has been at a standstill during the
last 3 decades. There is an urgent need for new active agents
in this disease entity. The topoisomerase I inhibitor topotecan
is active as both first and second line therapy.1–3 The combi-
nation with cisplatin has shown synergistic effects in preclin-
ical models.4 However, an unacceptable high frequency of
toxic deaths was associated with the administration of cispla-
tin on day 1 in combination with 5-day topotecan.5 As a
consequence the reverse sequence with cisplatin on day 5 has
been developed.6,7 In this report, we have modified the 5-day
schedule to a 3-day schedule to increase patient convenience.
The primary end point of the study was to estimate response
rate and response duration in chemo-naive extensive disease
SCLC patients receiving a 3-day topotecan schedule with
cisplatin on day 3. Secondary end points included toxicity
and overall survival.
PATIENTS AND METHODS
Eligibility Criteria
Patients with histologically or cytologically confirmed
extensive disease SCLC of the lung, including mixed histol-
ogy, who had received no prior radio- or chemotherapy were
eligible. Extensive disease was defined as disease beyond one
hemithorax or with the presence of ipsilateral pleural effusion
containing tumor cells. If the pathologic diagnosis was ob-
tained from a metastatic lesion, the presence of either patho-
logic mediastinal lymph nodes or a lung tumor was required
on the baseline computed tomography (CT) scan. Measurable
disease according to the response evaluation criteria in solid
tumors (RECIST) criteria was mandatory. Patients older than
64 years with poor prognostic factors [performance status
more than 1 or lactate dehydrogenase (LDH) more than 2
times above the upper limit of normal] were excluded. Inclu-
sion criteria were age between 18 and 75; performance status
less than 3; adequate organ functions including hemoglobin
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more than or equal to 6.0 mmol/liter, absolute neutrophil
count (ANC) count less than or equal to 1,500/mm3; platelet
count more than or equal to 100,000/mm3; bilirubin less than
or equal to 40 mmol/L; international normalized ratio less of
prothrombin time than 2 if not on antithrombotic treatment;
and normal renal function. No other antineoplastic treatments
for SCLC were allowed. Patients with a history of other
malignant diseases except non-melanoma skin cancer and
carcinoma in situ of the cervix were not eligible. Other
exclusion criteria were pregnancy, lactation, active uncon-
trolled infection, or medical conditions unrelated to SCLC
that—in the opinion of the treating physician—could expose
the patient to unnecessary risks. Contraceptive measures were
mandatory for fertile women. Written informed consent was
required. The study protocol was approved by the regulatory
authorities and ethical review boards. The study was con-
ducted according to the declaration of Helsinki.
Patient Evaluation
At baseline, patients underwent the following evalua-
tion: complete medical history including prior malignant
diseases, physical examination, revision of the pathology
report, weight, height, World Health Organization perfor-
mance status, electrocardiography, chest radiograph, CT scan
of the chest and upper abdomen (ultrasound study of the
abdomen could substitute for abdominal CT scan), double-
sided bone marrow aspiration with biopsy, bronchoscopy
and/or mediastinoscopy, 51Cr-ethylenediaminetetraacetic acid
(EDTA) or creatinine clearance, complete blood count, bio-
chemistry including LDH, alkaline phosphatase, aminotrans-
aminases, bilirubin, prothrombin time, albumin, sodium, po-
tassium, calcium, magnesium, creatinine, and dipstick urine
analysis. Brain scans were not routinely performed.
Treatment
Treatment consisted of six cycles of topotecan 2.0
mg/m2 on day 1 to 3 given intravenously (i.v.) over 30
minutes and cisplatin 50 mg/m2 i.v. on day 3. Cycles were
repeated every 3 weeks. Patients with progressive disease or
no-change after three cycles went off study. Patients were
hydrated with 1500 mL saline and 500 mL 10% mannitol
over 2 hours and with 2000 mL saline over 4 hours before and
after the administration of cisplatin, respectively. Antiemetics
included a 5-HT3 receptor antagonist, steroids, and metoclo-
pramide or metopimazine according to standard procedures at
the participating centers.
Dose modifications: Treatment on day 1 was withheld
1 week if ANC was less than 1,500/mm3 or platelet count was
less than 75,000/mm3. If hematologic recovery was not
reached after 1 week, patients went off study. Topotecan was
reduced to 75% if one of the following events occurred: ANC
nadir of 500/mm3 or lower for more than 5 days; ANC nadir
of 500/mm3 or lower of any duration in combination with
fever of more than 38.5°C or infection; platelet count nadir of
25,000/mm3 or lower for more than 5 days. Patients went off
study if renal clearance dropped below 40 mL/min or in the
event of grade 3 or 4 oto- or neurotoxicity.
End Point Evaluation
The primary end points of the study were response rate
and response duration. Response assessment was performed
according to RECIST in solid tumors criteria. Confirmation
of response was required minimum 4 weeks after the re-
sponse was initially recorded. Response duration was defined
as the time from the first day of treatment to documented
progression or death due to SCLC in patients achieving a
partial or complete response. Follow-up visits including med-
ical history, physical examination, biochemistry, and chest
radiograph were performed every third month. Secondary end
points were toxicity, median and 2-year survival. Toxicity
was graded according to National Cancer Institute Common
Toxicity Criteria version 2.0. Survival was defined as the time
from the first day of treatment to the date of death.
Statistics
Simons optimal two-stage design was used.8 If the true
response rate (complete and partial responses) was at least
70%, the regimen was to be regarded as active supporting
further evaluation in phase III trials. No further development
of the regimen was justified if the true response rate was less
than 50%. A risk of 5% () of completing the study although
the true response rate was lower than 50% was accepted.
Furthermore, a probability of 20% () of rejecting the regi-
men even though the true response rate was at least 70% was
allowed. Under these conditions, the trial should be stopped
after the first stage if eight patients or less responded out the
first 15 patients enrolled. The regimen was regarded as active
and suitable for further clinical development, if 26 patients or
more responded out of a total number of 43 patients enrolled.
The method of Kaplan-Meier was used to estimate median
response duration and overall survival. Patients who were lost
for follow-up or died of causes other than progression were
censored in the response duration analysis.
RESULTS
Patient Characteristics
From May 2001 to September 2003, 43 patients from
six Danish centers were enrolled. Sixty-three percent of
patients were male. Median age was 59 years. Seventy-nine
percent of patients had performance status 0 or 1. All patients
had elevated LDH, and in two thirds of the patients the LDH
was more than twice the upper limit of normal (Table 1).
Compliance
A total of 219 cycles of chemotherapy was adminis-
tered. Seventy-six percent and 83% of the planned doses of
topotecan and cisplatin were delivered. All patients received
at least one cycle of chemotherapy. Thirty-one patients com-
pleted all six cycles. Reasons for failure of completing the
scheduled cycles were progressive disease (n  6), toxicity
(n 2), both progressive disease and toxicity (n 1), lack of
clinical benefit due to mixed response (n  1), fatal cardiop-
ulmonal event (n  1). One patient died after surgery for a
non-malignant bowel obstruction.
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Toxicity
Hematologic toxicity was frequent. Grade 3 and 4
anemia, neutrocytopenia and thrombocytopenia were re-
corded in 9.5%, 66.7%, and 21.4% of patients, respectively
(Table 2). Six episodes of neutropenic fever were reported
corresponding to a frequency of 2.7% of courses (6 of 219) or
14.0% of patients (6 of 43). No episodes of fatal sepsis
occurred. A median of two blood transfusions were infused to
a total of 24 patients. No patients required pooled platelets
during the treatment. One patient went off study after two
cycles due to hearing loss. Treatment was postponed in 7.3%
of cycles because of toxicity. Dose reductions were necessary
due to hematological and non-hematologic toxicity in 9.6%
and 3.7% of cycles, respectively. Non-hematologic toxicity
was mild and manageable (Table 3). Grade 3 and 4 toxicities
were infrequent. The most frequent toxicity was nausea. The
median decrease in GFR was 9.0 mL/min in 24 patients with
both a pre- and posttreatment measurement of 51Cr-EDTA
acid-clearence available. Three patients had a Glomerular
Filtration Rate below 50 mL/min posttreatment.
Six patients died while on treatment. Causes of death
were obvious progressive disease in three cases. One patient
with a central tumor died at home because of fatal hemopty-
sis. Platelet count was 61 the preceding day. The most likely
cause of death was tumor invasion into pulmonary vessels.
However, a causal relationship to therapy cannot be com-
pletely excluded. One patient with dyspnea and chest pain
died 22 days after the first cycle of chemotherapy. The cause
of death was probably pulmonary embolism based on a right
bundle branch block on the electrocardiograph, elevated fi-
brin D-dimer and normal creatinine kinase and troponin T.
One patient died 3 days after surgery for a bowel obstruction
considered secondary to radiotherapy delivered 51 days be-
fore death. Immediately after the completion of the second
cycles on day 4, radiotherapy (4 Gy in seven daily fractions)
was delivered due to tumor involvement of the sacral nerve
plexus. The patient developed irradiation induced colitis. The
study treatment may have contributed to the severity of colitis
and the fatal outcome due to the small time interval between
chemo- and radiotherapy.
Efficacy
Based on intension-to-treat, the overall and complete
response rates were 72.1% and 9.3%, respectively (Table 4).
The median overall survival was 10.3 months (95% confi-
dence interval, 8.6–12.0) (Figure 1). The 2-year survival rate
was 8%. The median response duration was 7.0 months (95%
confidence interval, 6.3–7.7). Twenty-three patients (53%)
received second line therapy.
DISCUSSION
Ongoing DNA synthesis is a prerequisite for topoisom-
erase I induced cell death. Transient topoisomerase I induced
TABLE 1. Patient Characteristics
No. Patients (n) Percent of Patients (%)
Gender
Male 27 62.8
Female 16 37.2
Performance status
PS  0 12 27.9
PS  1 22 51.2
PS  2 4 9.3
Unknown 5 11.3
LDH
Normal 0 0
2  ULN 13 30.2
2  ULN 29 67.4
Unknown 1 2.3
Sodium
Low 17 39.5
Normal 25 58.1
High 1 2.3
Median age (range) 59 (44–74)
ULN, upper limit of normal.
TABLE 2. Hematologic toxicity
Reference
Topotecan Dose
(mg/m2)
Cisplatin Dose
(mg/m2)
Grade 3/4
Anemia (%)
Grade 3/4 Throm-
Bopenia (%)
Grade 3/4 Neutro-
Penia (%)
Grade3/4 Leuco-
Penia (%)
aQouix et al.18 1.25 d 1–5 50 d 5 46.4 31.7 87.8 39.1
bHerzog et al.11 2.0 d 1–3 — 16 13 90 58
aSeifart et al.17 1.0 d 1–5 75 d 5 42.9 52.4 64.3
aSeifart et al.17 1.5 d 1–3 75 d 3 21.4 40.4 47.6
a,cPresent study 2.0 d 1–3 50 d 3 9.5 21.4 66.7
Hematologic toxicity per patient compared with other studies of topotecan followed by cisplatin or topotecan alone. All schedules were administered every 3 wk.
a chemo-naïve extensive disease SCLC.
b Recurrent ovarian cancer.
c No data available in one patient due to early death.
TABLE 3. Non-hematologic Toxicity
Grade 1  2
(%a)
Grade 3  4
(%a)
Nausea/vomiting 66 5
Neurotoxicity 22 2
Ototoxicity 10 5
Allergy 2 2
Renal toxicity 24 0
a Percent per patient.
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DNA single strand breaks are converted into permanent and
lethal DNA strand breaks when the DNA replication fork
collides with a DNA single strand break.9 These insights into
the mechanism of action prompted clinical development of
schedules with prolonged drug exposure including the now
recommended 5-day schedule of topotecan. However, a 5-day
schedule seems inconvenient and shorter schedules are war-
ranted to reduce in-hospital stays for patients in the palliative
setting. In ovarian cancer a 3-day monotherapy schedule has
been developed using a dose of 2.0 mg/m2 topotecan. Al-
though no comparative trials have been performed, phase II
data indicate that efficacy of the 3-day schedule is preserved
compared with the conventionally used 5-day schedule.10–12
Furthermore, the S phase specific topoisomerase II inhibitor,
etoposide, seems active when given as part of a 3-day
regimen. Thus, clinical data indicate that drug exposure can
be reduced to less than 5 days with preservation of efficacy.
A decade ago it was established that the combination of
a topoisomerase I inhibitor with a platinum results in a
synergistic tumor cell kill in in vitro model systems.4,13
Randomized trials have confirmed that the combination is
very active and prolongs survival in cervical cancer14 and
extensive disease SCLC.15 In an early phase I study, a 5-day
topotecan schedule followed by cisplatin on day 1 was found
safe and feasible.16 However, the same group subsequently
reported an unacceptable high rate of fatal sepsis.5 Rowinsky
et al. showed that hematologic toxicity is highly sequence
dependent. In their phase I study, cisplatin was either given
on day 1 or day 5 with topotecan given on day 1 through 5.
The combination was far better tolerated when cisplatin was
given after topotecan.6 We later showed that the maximum-
tolerated dose of topotecan with 50 mg/m2 cisplatin on day 5
was equivalent to the recommended dose of topotecan as
single agent i.e., 1.5 mg/m2 topotecan.7
We now report a phase II study that integrate these two
concepts, i.e., a shorter drug exposure and combination with
cisplatin. A 3-day schedule was used with cisplatin on day 3.
The regimen was feasible with 72% of all patients (31 of 43)
completing all six cycles. Disease progression was the most
frequent reason for interrupting treatment. The combination
was safe. No episodes of fatal sepsis occurred. The frequency
of grade 3 and 4 neutropenia (66.7%) compares favorable to
90% neutropenia and 58% leucocytopenia reported in recur-
rent ovarian cancer patients treated with 2.0 mg/m2 topotecan
in 3 days without cisplatin.11 Presumably, the variation in
myelosuppression reflects whether topotecan is given as first-
or second-line treatment. Interestingly, thrombocytopenia
was more frequent in our study (21.4%) and other studies17,18
combining topotecan with cisplatin compared with second-
line single-agent topotecan in the ovarian cancer population
(13%).11 The increased thrombocytopenia could be caused by
a combined effect of cisplatin and topotecan. A German
randomized phase II trial compared 3-day (1.0 mg/m2 i.v.)
with 5-day topotecan (1.5 mg/m2 i.v.) followed by cisplatin
(75 mg/m2 i.v.) in chemo-naive SCLC patients with extensive
disease.17 Grade 3 and 4 thrombocytopenia and anemia in the
3-day arm of the German study were approximately double
that seen in the present study (40.4% and 21.4% versus
21.4% and 9.5%) using a higher topotecan and lower cisplatin
dose than in German study. Myelosuppression was reported
as leukocyte and neutrofilocyte count in the two studies,
respectively, which hampers a direct comparison. However,
leucocytopenia of 47.6% in the German trial seems in the
range of a neutropenia frequency of 66.7% reported in our
study (Table 2). Again, the increased thrombocytopenia and
anemia might be an effect of the higher dose of cisplatin used
in the German trial. This hypothesis is in accordance with
data showing that the degree of hematologic toxicity in-
creases when topotecan and cisplatin are combined.6 A re-
sponse rate of 72% in the intension-to-treat population and a
median survival of 10.3 months compares favorable to a
response rate of 60% and median survival of 7.6 months in
3-day arm of the German study.17 As the response rate
reached in the present study was beyond the prespecified
criteria, the combination seems suitable for further clinical
development. Thus, the Danish Oncological Lung Cancer
Group launched a nationwide phase III randomized trial that
compares this regimen to a standard etoposide/platinum com-
bination. A number of trials randomizing between a topo I
and a topo II inhibitor in combination with a platinum have
reached conflicting results. An impressive 3.4 months sur-
vival benefit favoring irinotecan/cisplatin compared with eto-
FIGURE 1. Overall survival. The median overall survival was
10.3 months (95% CI: 8.6–12.0).
TABLE 4. Response
No. of
Patients (N)
Percent of
Patients (%) 95% CI
Complete response 4 9.3 0.6–18.0
Partial response 27 62.8 48.3–77.2
Overall response 31 72.1 58.7–85.5
No change 4 9.3 0.6–18.0
Progressive disease 1 2.3 0–6.8
Not evaluable 7 16.3 5.2–27.3
Total 43 100 —
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poside/cisplatin in a preplanned interims analysis of 134
patients reported by the Japanese Cooperative Oncology
Group (JCOG)15 prompted North American investigators to
initiate two confirmative trials. In a larger study with a
slightly modified schedule, the encouraging Japanese results
could not be confirmed.19 The South West Oncology Group
has completed a replicate trial that uses the exact same
schedule as the JCOG trial and this trial has yet to be
reported. In contrast, two European trials substituting cis-
with carboplatin lend some support to the JCOG data. A
slight but significant survival benefit of 1.3 months was found
in the irinotecan arm of the Norwegian IRIS trial randomizing
210 patients with extensive disease.20 A German phase II
study randomizing 70 patients was extended to a phase III
trial due to a significant increase in the median progression-
free survival from 6 to 9 months in favor of the irinotecan/
carboplatin arm.21 In one of the largest randomized trials ever
conducted in SCLC, oral topotecan in combination with
cisplatin was non-inferior to intravenous etoposide/cisplatin
with respect to survival.22 The oral formulation of topotecan
is claimed to be as efficacious as the intravenous formulation.
However, comparisons of the two administration forms have
only been done in the second line setting in two underpow-
ered randomized studies.23,24 Both the frequency of clinical
benefit (35.9% versus 45.1%) and progression-free survival
(11.9 versus 14.6 weeks) favored numerically the intravenous
administration in the largest trial.23 Thus, the role of first line
intravenous topotecan in combination cisplatin remains to be
determined. An ongoing Danish Oncological Lung Cancer
Group trial aims to contribute to the resolvement of this
question.
ACKNOWLEDGMENTS
Supported by a grant from GlaxoSmithKline, Denmark.
We are indebted to the patients and their families for
their participation in this trial. We thank statistician Knud
Nelausen for the construction of the database in CITMAS. We
also thank study nurses Carsten Nielsen and Hanne Mich-
elsen for their expert data management.
REFERENCES
1. Schiller JH, Kim K, Hutson P, et al. Phase II study of topotecan in
patients with extensive-stage small-cell carcinoma of the lung: an
Eastern Cooperative Oncology Group Trial. J Clin Oncol 1996;14:2345–
2352.
2. Ardizzoni A, Hansen H, Dombernowsky P, et al. Topotecan, a new
active drug in the second-line treatment of small-cell lung cancer: a
phase II study in patients with refractory and sensitive disease. The
European organization for research and treatment of cancer early clinical
studies group and new drug development office, and the lung cancer
cooperative group. J Clin Oncol 1997;15:2090–2096.
3. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclo-
phosphamide, doxorubicin, and vincristine for the treatment of recurrent
small-cell lung cancer. J Clin Oncol 1999;17:658–667.
4. Kaufmann SH, Peereboom D, Buckwalter CA, et al. Cytotoxic effects of
topotecan combined with various anticancer agents in human cancer cell
lines. J Natl Cancer Inst 1996;88:734–741.
5. Miller AA, Lilenbaum RC, Lynch TJ, et al. Treatment-related fatal
sepsis from topotecan/cisplatin and topotecan/paclitaxel. J Clin Oncol
1996;14:1964–1965.
6. Rowinsky EK, Kaufmann SH, Baker SD, et al. Sequences of topotecan
and cisplatin: phase I, pharmacologic, and in vitro studies to examine
sequence dependence. J Clin Oncol 1996;14:3074–3084.
7. Sorensen M, Jensen PB, Herrstedt J, et al. A dose escalating study of
topotecan preceding cisplatin in previously untreated patients with
small-cell lung cancer. Ann Oncol 2000;11:829–835.
8. Simon R. Optimal two-stage designs for phase II clinical trials. Control
Clin Trials 1989;10:1–10.
9. Ryan AJ, Squires S, Strutt HL, et al. Camptothecin cytotoxicity in
mammalian cells is associated with the induction of persistent double
strand breaks in replicating DNA. Nucleic Acids Res 1991;19:3295–
3300.
10. Brown JV, Peters WA, Rettenmaier MA, et al. Three-consecutive-day
topotecan is an active regimen for recurrent epithealial ovarian cancer.
Gynecol Oncol 2003;88:136–140.
11. Herzog TJ, Powell MA, Rader JS, et al. Phase II evaluation of a 3-day
infusion of topotecan in patients with recurrent ovarian or primary
peritoneal cancer. Gynecol Oncol 2006;103:637–641.
12. Markman M, Kennedy A, Webster K, et al. Phase 2 evaluation of
topotecan administered on a 3-day schedule in the treatment of platinum-
and paclitaxel-refractory ovarian cancer. Gynecol Oncol 2000;79:116–
119.
13. Romanelli S, Perego P, Pratesi G, et al. In vitro and in vivo interaction
between cisplatin and topotecan in ovarian carcinoma systems. Cancer
Chemother Pharmacol 1998;41:385–390.
14. Long HJ III, Bundy BN, Grendys EC Jr, et al. Randomized phase III trial
of cisplatin with or without topotecan in carcinoma of the uterine cervix:
a Gynecologic Oncology Group Study. J Clin Oncol 2005;23:4626–
4633.
15. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin
compared with etoposide plus cisplatin for extensive small-cell lung
cancer. N Engl J Med 2002;346:85–91.
16. Miller AA, Hargis JB, Lilenbaum RC, et al. Phase I study of topotecan
and cisplatin in patients with advanced solid tumors: a cancer and
leukemia group B study. J Clin Oncol 1994;12:2743–2750.
17. Seifart U, Jensen K, Ukena J, et al. A randomized phase II study
comparing topotecan/cisplatin administration for 5 days versus 3 days in
the treatment of extensive stage small cell lung cancer (SCLC). Lung
Cancer 2005;48:415–422.
18. Qouix E, Breton J-L, Gervais R, et al. A randomised phase II study of
the efficacy and safety of intravenous topotecan in combination with
either cisplatin or etoposide in patients with untreated extensive disease
small-cell lung cancer. Lung Cancer 2005;49:253–261.
19. Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase III trial
comparing irinotecan/cisplatin with etoposide/cisplatin in patients with
previously untreated extensive-stage disease small-cell lung cancer.
J Clin Oncol 2006;24:2038–2043.
20. Hermes A, Bergman B, Bremnes R, et al. A randomized phase III trial
of irinotecan plus carboplatin versus etoposide plus carboplatin in
patients with small cell lung cancer, extensive disease (SCLC-ED):
IRIS-Study. Proc Am Soc Clin Oncol 2007;25:7523.
21. Schmittel A, Fischer von Weikersthal L, Sebastian M, et al. A random-
ized phase II trial of irinotecan plus carboplatin versus etoposide plus
carboplatin treatment in patients with extended disease small-cell lung
cancer. Ann Oncol 2006;17:663–667.
22. Eckardt JR, von Pawel J, Papai Z, et al. Open-label, multicenter,
randomized, phase III study comparing oral topotecan/cisplatin versus
etoposide/cisplatin as treatment for chemotherapy-naive patients with
extensive-disease small-cell lung cancer. J Clin Oncol 2006;24:2044–
2051.
23. Eckardt JR, von Pawel J, Pujol JL, et al. Phase III study of oral compared
with intravenous topotecan as second-line therapy in small-cell lung
cancer. J Clin Oncol 2007;25:2086–2092.
24. von Pawel J, Gatzemeier U, Pujol JL, et al. Phase II comparator study of
oral versus intravenous topotecan in patients with chemosensitive small-
cell lung cancer. J Clin Oncol 2001;19:1743–1749.
Sorensen et al. Journal of Thoracic Oncology • Volume 3, Number 8, August 2008
Copyright © 2008 by the International Association for the Study of Lung Cancer906
